ArticleGeroScience2022
Cardiovascular risk prediction in healthy older people.
Article in GeroScience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Machine-learning versus traditional approaches for atherosclerotic cardiovascular risk prognostication in primary prevention cohorts: a systematic review and meta-analysis.European heart journal. Quality of care & clinical outcomes · 2023Pooled it
- Associations between MASLD, atrial fibrillation, cardiovascular events, mortality and aspirin use in older adults.GeroScience · 2025Trial
- Walking Pace Optimizes Conventional Cardiovascular Disease Risk Prediction Models Among Vulnerable Subpopulations: A Prospective Cohort Study.Journal of the American Heart Association · 2026Article
- The Pan-Immune-Inflammation Value (PIV) predicts major adverse cardiovascular events in elderly patients undergoing percutaneous coronary intervention: a real-world study.BMC cardiovascular disorders · 2026Article
- Loss of Y Chromosome and Major Cardiovascular Events in a Prospective Study of Older Men.Journal of the American College of Cardiology · 2026Article
- Web-based cardiovascular disease risk prediction using machine learning.Frontiers in artificial intelligence · 2026Article
- Digital intelligence for cardiometabolic health management in older adults: protocol for a community-based prospective cohort study.BMC geriatrics · 2025Article
- Cardiovascular Risk Prediction in Older Adults.Current atherosclerosis reports · 2025Review
- Challenges in the prevention, treatment and management of cardiovascular disease among older adults.The Lancet regional health. Europe · 2025Review
- Genetic Variants, Metabolic Dysfunction-Associated Fatty Liver Disease, and Major Health Outcomes in Older Adults.Biomedicines · 2025Article
- Article
- Prevalence and outcomes of steatotic liver disease subtypes in older adults.Hepatology communications · 2025Article
- Review
- Integrating Social Determinants of Health and Established Risk Factors to Predict Cardiovascular Disease Risk Among Healthy Older Adults.Journal of the American Geriatrics Society · 2025Article
- Classification rule for ten year MACE Risk in primary care tarragona older adults with type2 diabetes: a CHAID decision-tree analysis.BMC primary care · 2025Article
- Modest NT-proBNP Elevation in Septuagenarians Without Heart Failure Is Not Associated with Cardiac Alterations or Cardiovascular Outcomes.Journal of clinical medicine · 2025Article
- The mediating and joint effects of depression in the association between cardiovascular health and frailty in middle-aged and elderly people: evidence from NHANES.Frontiers in psychiatry · 2025Article
- Metabolic syndrome with mortality and major adverse cardiovascular events in an elderly population.Frontiers in endocrinology · 2025Article
- Sex differences in 10-year cardiovascular risk of patients with type 2 diabetes mellitus and subclinical hypothyroidism: a cross-sectional study.Frontiers in endocrinology · 2025Observational
- Bias in machine learning applications to address non-communicable diseases at a population-level: a scoping review.BMC public health · 2024Article
Corrections and comments
- Commented on by
Authors and funding
13 authors.
Funding
Abstract
Identification of individuals with increased risk of major adverse cardiovascular events (MACE) is important. However, algorithms specific to the elderly are lacking. Data were analysed from a randomised trial involving 18,548 participants ≥ 70 years old (mean age 75.4 years), without prior cardiovascular disease events, dementia or physical disability. MACE included coronary heart disease death, fatal or nonfatal ischaemic stroke or myocardial infarction. Potential predictors tested were based on prior evidence and using a machine-learning approach. Cox regression analyses were used to calculate 5-year predicted risk, and discrimination evaluated from receiver operating characteristic curves. Calibration was also assessed, and the findings internally validated using bootstrapping. External validation was performed in 25,138 healthy, elderly individuals in the primary care environment. During median follow-up of 4.7 years, 594 MACE occurred. Predictors in the final model included age, sex, smoking, systolic blood pressure, high-density lipoprotein cholesterol (HDL-c), non-HDL-c, serum creatinine, diabetes and intake of antihypertensive agents. With variable selection based on machine-learning, age, sex and creatinine were the most important predictors. The final model resulted in an area under the curve (AUC) of 68.1 (95% confidence intervals 65.9; 70.4). The model had an AUC of 67.5 in internal and 64.2 in external validation. The model rank-ordered risk well but underestimated absolute risk in the external validation cohort. A model predicting incident MACE in healthy, elderly individuals includes well-recognised, potentially reversible risk factors and notably, renal function. Calibration would be necessary when used in other populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.